© Synapse Social LLC, 2026
September 5, 2025 Supplementary Figure 4 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer GV Gillian Vandekerkhove BC Cancer Agency AM Andrew J. Murtha University of British Columbia DM David C. Müller University of British Columbia
See all Key Points Circulating tumor DNA analysis identifies double minutes, indicating genetic alterations in cancer cells. Whole-genome sequencing highlights the presence of HER2 alterations in ctDNA, suggesting a potential target for therapy. This investigation provides insights into the genetic landscape of metastatic urothelial cancer via tumor DNA analysis. The findings may enhance monitoring strategies for patients with metastatic urothelial cancer through ctDNA assessment. Abstract Supplementary Figure 4. Double minute (DM) inferred from whole-genome sequencing of circulating tumor DNA.
Vandekerkhove et al. (Tue,) studied this question.
Supplementary Figure 4 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer | Synapse
Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer 2025